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Background: Patients with metastatic melanoma have a poor median rate of survival. It is therefore necessary to
increase our knowledge about melanoma cell dissemination which includes extravasation, where cancer cells cross
the endothelial barrier. Extravasation is well understood during travelling of white blood cells, and involves integrins
such as LFA-1 (composed of two chains, CD11a and CD18) expressed by T cells, while ICAM-1 is induced during
inflammation by endothelial cells. Although melanoma cell lines cross endothelial cell barriers, they do not express
LFA-1. We therefore hypothesized that melanoma-endothelial cell co-culture might induce the LFA-1/ICAM ligand/
receptor couple during melanoma transmigration.
Methods: A transwell approach has been used as well as blocking antibodies against CD11a, CD18 and ICAM-1. Data
were analyzed with an epifluorescence microscope. Fluorescence intensity was quantified with the ImageJ software.
Results: We show here that HUVEC-conditioned medium induce cell-surface expression of LFA-1 on melanoma cell
lines. Similarly melanoma-conditioned medium activates ICAM-1 expression in endothelial cells. Accordingly blocking
antibodies of ICAM-1, CD11a or CD18 strongly decrease melanoma transmigration. We therefore demonstrate that
melanoma cells can cross endothelial monolayers in vitro due to the induction of ICAM-1 and LFA-1 occurring during
the co-culture of melanoma and endothelial cells. Our data further suggest a role of LFA-1 and ICAM-1 in the
formation of melanoma cell clumps enhancing tumor cell transmigration.
Conclusion: Melanoma-endothelial cell co-culture induces LFA-1 and ICAM-1 expression, thereby favoring in vitro
melanoma trans-migration.
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Metastatic melanoma account for most skin cancer
deaths. When diagnosed early, primary, non-disseminated,
tumors are successfully eliminated through excision. How-
ever, in about 20% of the cases, dissemination of tumor
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reproduction in any medium, provided the orto chemotherapy, with a median survival rate of 6 months
[1]. Uncovering molecules required for melanoma metas-
tasis is therefore essential.
Hematogenous metastasis of cancer consists of sev-
eral steps enabling cancer cells to intravasate, to sur-
vive in the blood circulation and to adhere to the
vessels, eventually extravasating and establishing new
metastatic lesions. Extravasation of most cancer cells
largely mimics leukocyte transendothelial migration
from the blood flow into sites of tissue inflammation
[2]. This controlled process involves the multistep ac-
tion of traffic signals and adhesion molecules thatLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion of lymphocytes [3].
The role of cell adhesion molecules (CAMs), such
as intercellular cell adhesion molecule-1 (ICAM-1), vas-
cular endothelial cell adhesion molecule-1 (VCAM-1),
E-selectin, and P-selectin, has been studied extensively in
the process of inflammation [4]. Indeed, leukocyte adhe-
sion during inflammation is thought to proceed in a
cascade-like fashion, in which selectins are responsible for
leukocyte capture and rolling, and integrins for mediating
firm adhesion and transmigration [5,6]. Among these
integrins, Leukocyte Function-Associated antigen-1 (LFA-
1; αLβ2) composed of two chains, CD11a and CD18, has
been extensively described for its essential role in
leukocyte extravasation [2,7]. It functions as a receptor for
ICAM-1 (CD54) [8-10]. Besides its role in the firm adhe-
sion of leukocytes to the endothelium, it appears domin-
ant in transendothelial migration [7,11]. In addition
numerous studies have shown that complete inhibition of
CD18, or genetic mutations in CD18 profoundly reduce
leukocyte transmigration at sites of inflammation [12].
Junctional Adhesion Molecules A (JAM-A) can also
interact with LFA-1 via its second membrane-proximal
Ig domain [13,14]. During leukocyte transendothelial mi-
gration, the homophilic transendothelial interactions be-
tween two molecules of JAM-A must be disrupted to
enable a migrating leukocyte to pass through junctions
[15] and it has been evidenced that LFA-1 binding to
JAM-A destabilizes the JAM-A homophilic interaction,
thus allowing transendothelial migration to proceed [16].
LFA-1 has been studied in different tumors, for in-
stance myelomas and gastrointestinal carcinomas. It has
been shown that expression of LFA-1 correlates with the
aggressiveness of myeloma [17] and is present in meta-
static gastrointestinal carcinomas [18].
In melanoma cell lines, LFA-1 cell-surface expression
is not detected. Towards a molecular explanation to the
high capacity of melanoma tumor cells to metastase, two
groups proposed that melanoma cells interact with neu-
trophils, thereby suggesting that neutrophils might be
used as carriers by the tumor cells [19-21]. Liang et al.
[19] have notably demonstrated that under IL-8 signal-
ing, melanoma interact with polymorphonuclear neutro-
phils (PMNs) through the binding between ICAM-1 on
melanoma cells and β2 integrins on PMNs. The authors
also showed that this interaction facilitates melanoma
cell adhesion to the endothelial cells and subsequent
extravasation by a shear-rate dependent mechanism [21].
However during our studies of melanoma metastasis,
we observed that melanoma cell lines have the cap-
acity to transmigrate through endothelial monolayers
in the absence of PMNs. We therefore hypothesized
that melanoma-endothelial cell co-culture might induce
the ICAM-1/LFA-1 ligand-receptor interaction. In thismanuscript we studied three human melanoma cell
lines with differential transmigration capacities. We
provide evidence that melanoma supernatants induce
ICAM-1 expression on HUVEC cells, and that LFA-1
can be detected on melanoma cell lines when using
HUVEC-conditioned medium. Further confirmation
was obtained through the use of either ICAM-1 or
LFA-1 blocking antibodies introduced during the co-
culture and show that they strongly impair melanoma
transmigration.
Material and methods
Cell lines and cell culture
The melanoma cell line SLM8 kindly provided by M.
Viguier (Service de dermatologie, Hopital Saint-Louis,
Paris, France), is derived from a lymph node metastasis.
The 1205LU cell line, a generous gift by A. Mauviel
(Institut Curie/CNRS UMR 3347/Inserm U1021), is
derived from the lung metastatic WM793 cell line. The
A375 cell line was purchased from the ATCC. HUVEC
cells were kindly provided by C. Nahmias (Institut
Cochin, Paris, France). A375, 1205LU and SLM8 human
cell lines were grown in DMEM/F12 (Invitrogen, Cergy-
Pontoise, France) supplemented with antibiotics and
10% fetal calf serum (FCS) in a 5% CO2 atmosphere
(hereafter named FCS complete medium). HUVEC cells
have been cultured in high glucose DMEM containing
glutamax, 1% antibiotics and 10% FCS in a 5% CO2
atmosphere.
Conditioned medium
To obtain conditioned medium cells were grown to con-
fluence during 48hrs before collecting the supernatant.
The medium was diluted to 3/4 with FCS complete
medium (1/4) then added for 24hrs to the target cells
plated at 80% of confluence. The basal negative control
was obtained with only FCS complete medium.
RNA extraction and semi-quantitative PCR
Total RNA was extracted using the RNeasy kit (Qiagen,
Courtaboeuf, France) following the manufacturer’s instruc-
tions. cDNA was synthesized from 2 μg of total RNA using
400 ng oligo(dT) (Invitrogen, Cergy-Pontoise, France), 20
units RNAsin RNase inhibitor (Promega, Madison,
Wisconsin, USA) and 8 units Omniscript reverse transcript-
ase following the manufacturer’s instruction. PCR was per-
formed by an initial denaturation step at 95°C for 5 min,
followed by 30 cycles at 95°C for 45s, 60°C for 45s
(GAPDH) and 72°C for 1min. Primer sequences for human
GAPDH were: 50–GTCGTATTGGGCGCCTGGTCAC–30
and 50–AGGGGCCATCCACAGTCTTCTG–30. All primer
sequences, hybridization temperature, number of cycles
and PCR conditions for other genes tested are summarized
in Table 1.
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Cells (5 × 105) treated with conditioned medium from a
48hrs of HUVEC cells culture were harvested in cold
phosphate-buffered saline (PBS) containing 1 mM ethy-
lenediaminetetraacetic acid (EDTA) and incubated for
20 min with 2% fetal calf serum in PBS. Specific direct
primary antibodies CD11a antibody (FAB35951A) and
CD18 (FAB1730P) from R&D system (Minneapolis, MN,
USA) or isotypic control antibody (BD Pharmingen, San
Diego, CA, USA) were used at 1 μg ml. After three
washes, cell death was monitored by propidium iodide
(5 μg ml) uptake and fluorescence was analyzed in a cyt-
ometer from DAKO (Trappes, France).
Trans-endothelial migration of melanoma
Trans-endothelial migration of melanoma was performed
as previously described [22]. Briefly, 5 × 104 HUVEC
cells were seeded on 2mg/ml type I collagen-coated
Transwell culture inserts with 8 μm pores (Greiner Bio-
One SAS, Courtaboeuf, France) and grown for 2 days.
Melanoma cells were labeled with 10 μM of the lipophilic
fluorescent dye DiO (Molecular Probes, Invitrogen,
Cergy-Pontoise, France) for 20 minutes at 37°C. 5×104
fluorescent melanoma cells were added to wells con-
taining either 1μg/ml of isotypic control (IgG from BD
Pharmingen, San Diego, CA, USA); or anti-CD11a
(ab3981; Abcam; Paris, France), anti-CD18 (ab8220;
Abcam; Paris, France) or anti-ICAM-1 (MAB2146Z;
Millipore; Molsheim France) antibodies in the upper
chamber. A chemotactic gradient was created by addition
of 10% FCS to the lower chamber. Melanoma cells were
allowed to migrate at 37°C and 5% CO2 for 48 hours.
To remove non-migrating cells, the ones on the upper
face of the filter were gently scraped using a cotton
swab. Cells on the lower face were washed in PBS, fixed
with 4% formaldehyde for 10 min and washed in PBS.
Nuclei were then labeled with 1μg/ml DAPI for 5minTable 1 Primer sequences and PCR settings












Reverse AGGGGCCATCCACAGTCTTCTGand cells were washed again. The migrating melanoma
cells were observed under an epifluorescence micro-
scope using a magnification of x100. Three to five pic-
tures of adjacent fields of the central zone of each
Transwell were taken. Fluorescence intensity was quanti-
fied with the ImageJ software (US National Institutes of
Health, Bethesda, MD, USA). Histograms display the
data obtained with 3 independent experiments, and
all the experiments were performed in duplicate. The
p value has been calculated by an ANOVA statistical test.
Human cytokine array
The detection of cytokines’ production by the three mel-
anoma cell lines has been tested after 24hrs of culture in
12ml of culture medium using the Proteome ProfilerTM
Array Human Cytokine Array Panel A according to the
manufacturer’s instructions (ARY005; R&D systems
Minneapolis, USA). Hence, melanoma cells have been
tested on nitrocellulose membranes each containing 36
different anti-cytokine antibodies spotted in duplicate.
Experiments have been done in duplicate.
Results
Melanoma cells transmigrate through endothelial cells
Transwell experiments mimicking transendothelial migra-
tion were performed with three melanoma cell lines.
Briefly, HUVEC cells (Human Umbilical Vein Endothelial
Cells) are grown as a monolayer to confluence on a type I
collagen matrix layer poured onto a microporous mem-
brane. Melanoma cells, stained with a lipophilic fluores-
cent dye, are then allowed to cross this barrier for 48hrs.
The corresponding membranes of the Transwells are
photographed prior to the quantification of fluorescent
cancer cells, located at the lower part of the membrane.
As seen in Figure 1, all three cell lines have the cap-
acity to transmigrate. The A375 cell line presents the



















Figure 1 Differential transendothelial migrations of A375, 1205LU
and SLM8 cell lines. A HUVEC cells were seeded on type I collagen-
coated Transwell culture inserts. DiO-labelled melanoma cells were
added to the upper chamber and allowed to migrate for 48 h. Cells
on the lower face of the inserts were fixed and labeled with DAPI
prior to their observation under an epifluorescence microscope.
B The histograms represent the quantification of the data obtained
from 3 independent experiments, and all the experiments were
performed in duplicate. The A375 cell line was considered here as
having a 100% transmigration efficiency.
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gration. The 1205LU cells have an intermediate pheno-
type. Interestingly the efficiency of transmigration of
these cell lines appeared to correlate with the forma-
tion of clumps (Figure 1A). Indeed A375 cells tend to
aggregate as clumps whereas the SLM8 cells transmig-
rate mostly as single cells. 1205 LU cells displayed an
intermediate phenotype with a mixture of small clumps
and single cells. In order to determine the importance
of passive passage of melanoma cell lines, we per-
formed transwell experiments as described below with-
out HUVEC cell monolayer and without chemotactic
gradient. In these conditions, the ability of melanoma
cells to pass through the microporous membrane was
almost inexistent and no significant difference was
observed between the three cell lines (p value >0.05)
(data not shown).
These data indicate that melanoma cells have the
capacity in vitro to cross endothelial cell monolayer,
although PMNs are not present. We therefore studied
the molecular mechanisms leading to this phenomenon.
LFA-1 is involved in melanoma trans-endothelial
migration in vitro
None of the three melanoma cell line expresses the
LFA-1 subunits, CD11a or CD18 in classical culture
condition (data not shown). However, when cultured in
the presence of HUVEC supernatant for 24 hours, all
three cell lines display a weak but reproducible expres-
sion of both chains at their cell surface (Figure 2).
In order to value the importance of LFA-1 in melan-
oma transmigration, blocking antibodies specifically
directed against CD11a or CD18 were introduced during
the transmigration assays. An anti-IgG antibody was
used as a negative control. Concerning the two cell lines
which transmigrate the most efficiently, A375 and
1205LU, a decrease of their trans-endothelial migration
was observed when either CD11a or CD18 blocking
antibodies were present (Figure 3AB). With the SLM8
cell lines, neither CD18 nor CD11a blocking antibodies
affect the transmigration efficiency (Figure 3C).
Melanoma cell lines enhance the expression of ICAM-1 on
the HUVEC cells
In normal conditions, HUVEC are known to lack high
expression of ICAM-1. However, it has been shown that
this level is strongly increased under inflammation [9],
as exemplified on Figure 4A, where ICAM-1 transcript
expression is highly induced in HUVEC cells treated
with 100ng/ml of TNF-α and IFN-γ (Figure 4A).
As exogenous inflammation molecules are not used in
the transmigration assays displayed in this report, we
wondered if melanoma cell lines could induce ICAM-1
expression in HUVEC cells. To answer this question,conditioned medium was prepared from the melanoma
cell lines after 48hrs of culture. The HUVEC cell line
was next cultured with this conditioned medium and
ICAM-1 transcript expression was analyzed. Figure 4B
shows that ICAM-1 is up-regulated by the conditioned
medium originating from all three melanoma cell lines,
more efficiently with the A375 and 1205LU cell
supernatants.
Interestingly, when analyzing the effect of the condi-












Figure 2 Expression of CD11a and CD18 in melanoma A375, 1205LU and SLM8 cell lines with conditioned medium. Cell-surface expression
of CD11a and CD18 on indicated melanoma cell lines treated for 24 hrs with HUVEC conditioned medium was analyzed by flow cytometry.
Isotypic controls are represented as empty histograms and specific antibody-labelling is displayed as shaded histograms. Histograms obtained
with cells incubated with FCS-complete medium and labeled with specific antibodies, which overlap with the isotypic control are not shown.
Data from obtained with 3 independent experiments.
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also induced in HUVEC cells (data not shown). However
the profile of gene expression was slightly different from
the one obtained with IFN-γ and TNF-α. To identify the
cytokines produced by melanoma cells, a cytokine
array was next performed (Figure 5). Hence we
noticed that melanoma cells, mainly the A375 and
1205LU cell lines, which have the higher capacities of
transmigration, secrete pro-inflammatory cytokines,
namely GM-CSF and IL-6, which have been described
to up-regulate the expression of ICAM-1 [23,24]. Inaddition all three cell lines secrete molecules such as
IL-8 and CXCL-1 (Figure 5). We demonstrated that
cells positive for surface expression of ICAM-1 (data
not shown) also secrete sICAM-1, which has been
extensively published as being up regulated in many
tumors [25], notably in melanoma where it has been
shown to be associated with disease progression
[26,27] and proposed as a prognosis marker [28,29].
Of interest, and to corroborate with our hypothesis,
cell lines expressing high amounts of GM-CSF were








































































Figure 3 Effect of CD11a and CD18-blocking antibodies on the transendothelial migration of A375, 1205LU and SLM8 cell lines. The
experiments were performed as detailed in Figure 1, except that 2μg/ml of CD11a or CD18-blocking antibodies were introduced in the upper
chamber of the Transwells when indicated. Histograms represent 3 independent experiments. In each experiment each condition was analyzed
in duplicate.
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highest rate of transmigration. Alternatively, one might
propose that PAI-1 might be of interest for the
1205LU cell line transmigration, as PAI-1 was
reported to affect the degradation of the extracellular
matrix [32,33].
Having shown that melanoma cells can induce ICAM-1
expression on HUVEC cells, it was necessary to provide
evidence of ICAM-1 implication in the transmigration.
ICAM-1 blocking antibodies were assayed on the samecell lines. As seen on Figure 6 blocking ICAM-1 impairs
transmigration of A375 and 1205LU, but not that of
SLM8, which is consistent with our previous observations
of a poor expression of ICAM-1 on endothelial cells when
incubated with SLM8-conditioned medium.
We therefore conclude that preferentially the A375
and 1205LU melanoma cell lines can transmigrate
through the endothelial cells due to a binding between
ICAM-1 expressed by the HUVEC cells and LFA-


























Figure 5 Melanoma cell lines display different cytokine
expression profiles. A Melanoma cells were cultured for 24hrs in
12ml of DMEM added with 10% FCS. The supernatant was next
tested for the presence of 36 different cytokines. B The histograms
represent the quantification by Image J software of the spots
obtained on the nitrocellulose membranes. Data were obtained
















































Figure 4 Conditioned mediums from melanoma cell lines
enhance transcript expression of ICAM-1 in HUVEC cells.
Semi-quantitative PCRs were performed to detect expression of
ICAM-1 transcripts. A HUVEC cells were treated either with TNF-α
and IFN-γ at 100ng/ml or B with conditioned medium from A375
(H+A375), SLM8 (H+SLM8) and 1205LU (H+1205LU) after 48hrs of
cell culture. GAPDH is used as a DNA amount control. Data were
obtained from 3 independent experiments.
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As ICAM-1 expression is often detected on melanoma
cell lines, we hypothesized that clumps might assemble
due to an interaction of LFA-1 and ICAM-1, and that
this cell association might enhance melanoma transmi-
gration capacities as described in some tumors [34]. All
three melanoma cell lines express ICAM-1 and LFA-1 in
the presence of conditioned medium from HUVEC cells
(Figure 2). However only A375 and 1205LU form cell
clumps (Figure 7), suggesting that these sole cell lines
possess functional partners for the interaction. To fur-
ther confirm the role of LFA-1 in the generation of cell
clumps, we examined the persistence of clumps by using
CD11a and CD18 blocking antibodies. As shown in
Figure 7, clump formation is no longer observed when
A375 and 1205LU cell lines were treated with anti CD11a
and anti CD18. These treatments do not affect the morph-
ology of SLM8 cells. Consequently we propose that trans-
endothelial migration of melanoma would be a cooperat-
ing endeavor, with clumps favoring the binding to endo-
thelial cells via the presence of LFA-1 on melanoma cells.Discussion
The recruitment of lymphocytes to sites of inflammation
involves a sequence of rolling along capillary vessel walls,
followed by chemokine induced arrest and migration
across a tight layer of vascular endothelial cells [35,36]. In-
vasion of tumor cells to secondary sites is often compared
with lymphocyte transendothelial migration since several
common cell adhesion molecules, such as selectins and
integrins, are involved in both lymphocyte and tumor cell
migration. It has previously been shown that following se-
cretion of IL-8 in the tumor microenvironment, the PMN
facilitated melanoma extravasation via the binding of β2
integrins on PMNs and ICAM-1 on melanoma cells [37].
In a congress report, it was mentioned (although not con-
firmed through a publication) that the co-culture of
HUVEC cells and a melanoma cell line from a lymph node
metastasis promotes the expression of αVβ3 facilitating
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SLM8 IgG SLM8 anti-ICAM-1 
p= 0,586 
Figure 6 Effect of ICAM-1-blocking antibodies on the
transendothelial migration of A375, 1205LU and SLM8 cell lines.
The experiments were performed as detailed in Figure 1, except that
2μg/ml of ICAM-1-blocking antibodies were introduced in the upper
chamber of the Transwell when indicated. Histograms represent 3
independent experiments. In each experiment each condition was
analyzed in duplicate.
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ter receptor ICAM-1 in melanoma transmigration. To in-
vestigate this hypothesis we used three melanoma cell
lines displaying different efficiencies of transendothelial
migration but similar expression of the tested integrin.
With blocking antibodies against these integrins and
ICAM-1, we showed that LFA-1 promotes melanoma cells
transmigration in vitro. In addition we provide evidence
that LFA-1 seems to be responsible for clumps’ formation,which could enhance further their extravasation capacities.
This is consistent with previous reports examining the mi-
gration of dendritic cells [39] or extravasation of some
tumors [40,41].
The expression on melanoma cell lines of such mole-
cules which are normally expressed on immune cells
might appear unexpected. However other immune cell-
specific molecules have already been shown to be
expressed on these tumors. Indeed, we have previously
demonstrated that MHCII (major histocompatibility
complex, Class II), in contrast with melanocytes, is con-
stitutively expressed on melanoma cells. We have
reported that the deregulation of HLA-D genes is due to
the abnormal constitutive expression of the lymphocyte-
specific isoform of class II transactivator (B-CIITA) [42].
This expression is driven by the MAPK cascade [43] and
associated with tumour progression and metastatic dis-
semination [44]. MHCII is not the only immune protein
expressed by melanoma cells. Indeed, as exposed above,
LFA-1 is able to bind to JAM-A. In a previous publica-
tion [22] we provided evidence of the differential roles of
JAM proteins, usually expressed by lymphocytes, in mel-
anoma transendothelial migration, where JAM-C pro-
motes their transendothelial migration, while expression
of JAM-A inhibits this phenomenon. Although both
JAMs are described as adhesion molecules, JAM-A is
involved in the tight junctions’ maintenance of endothe-
lial cells [45] and it has been reported that LFA-1 bind-
ing to JAM-A destabilizes the JAM-A homophilic
interaction, thus disrupting this connection, and facilitat-
ing its transendothelial migration [16]. Since HUVEC
cells express JAM-A (data not shown) this phenomenon
could also be, in part, responsible for the transmigration
we observed, in conjunction with the interaction be-
tween LFA-1 of melanoma cells and ICAM-1 of endo-
thelium and with the formation of melanoma cell
clumps (Figure 8), Alternatively an interaction between
Mac-1 and ICAM-1 might be relevant, as anti-CD11b
antibodies can reduce SLM8 transmigration, while it
does not alter the migration of the two other cell lines
(data not shown).
Patients with metastatic melanoma have a reduced life
span in the range of 6 months. Limited therapeutic treat-
ments explain this poor prognosis. Our findings showing
that CD18 blockade impairs melanoma cell transmigra-
tion might provide a new tool to control melanoma
metastatic mechanism.
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Figure 8 Model of melanoma transmigration. According to these results and to those of our previous publication [22] a model of melanoma



















Figure 7 Effect of CD11 and CD18-blocking antibodies on the formation of clumps. A Semi-quantitative PCRs were performed to detect the
expression of the ICAM-1 transcript. GAPDH is used as a DNA amount control. B A375, 1205LU and SLM8 cell lines were treated with 2 μg/ml of
CD11a or CD18-blocking antibodies as indicated. Melanoma cells were labeled with DiO then fixed and labeled with DAPI prior to their
observation under an epifluorescence microscope using a magnification of x10. Data were obtained from 3 independent experiments.
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